Summary of Prime Medicine Conference Call - September 02, 2025 Company Overview - **Company**: Prime Medicine (PRME) - **CEO**: Allan Reine - **Focus**: Gene editing technologies, specifically Prime Editing Key Points Pipeline and Strategic Focus - Transition to a focused pipeline with three high-value programs: Wilson's disease, Alpha-1 antitrypsin deficiency (AATD), and cystic fibrosis [4][5] - Previous pipeline had 18 programs, now streamlined for better capital allocation [4] - Collaboration with Bristol-Myers Squibb (BMS) for ex vivo CAR-T therapies, with $110 million upfront and $185 million in potential preclinical milestones [6] Clinical Development Timeline - Expecting Investigational New Drug (IND) application for Wilson's disease in the first half of 2026 and for AATD shortly thereafter [5][26] - Clinical data for both programs anticipated in 2027, marking a significant year for value creation [5] Prime Editing Technology - Prime Editing is described as the most versatile gene editing technology, capable of correcting various types of mutations beyond what CRISPR and base editing can achieve [6][54] - The technology allows for the insertion of multiple base pairs and correction of frameshift mutations, offering a broad range of applications [6] Clinical Data and Proof of Concept - Achieved proof of concept in chronic granulomatous disease (CGD) with rapid engraftment observed in treated patients [9][10] - Discontinued the CGD program but plans to engage with the FDA based on the strength of the data [12] Market Opportunities - **AATD**: Approximately 100,000 patients with the mutation in the U.S., with 10,000 to 15,000 diagnosed cases. Potential market size estimated at $20 billion to $40 billion [23][24] - **Wilson's Disease**: Targeting mutations prevalent in 30% to 50% of patients in the U.S. and higher in Asian populations. Global market opportunity estimated at $20 billion to $40 billion [30][33] Competitive Landscape - Limited competition in Wilson's disease, while AATD has multiple competitors. Prime Medicine aims to be a best-in-class therapy for AATD based on preclinical data [16][17] - Differentiation in the market is emphasized, particularly in the ability to return patients to wild-type protein levels [17][18] Future Directions and Partnerships - Potential for future business development deals, particularly in cell therapy and neurological diseases [57][58] - Ongoing arbitration with BEAM regarding the AATD program, with resolution expected in the first half of 2026 [28] Financial Position - Recent financing in August extended cash runway into 2027, with a pro forma cash position of approximately $260 million [60] Closing Remarks - The CEO expressed excitement about the company's technology and strategy, highlighting the transition from a lab-based company to one with human clinical data and upcoming programs [61] Additional Insights - The company is focused on leveraging its technology for unmet medical needs while ensuring commercial viability [54][56] - Emphasis on the importance of delivery mechanisms for gene editing therapies, particularly in challenging tissues like the lung for cystic fibrosis [48][50]

Core Insights - CRISPR Therapeutics (CRSP) is the first company to market a CRISPR/Cas9-based therapy, achieving significant success with its gene therapy Casgevy for sickle cell disease and transfusion-dependent beta-thalassemia [1][2] - The company is transitioning focus from ex vivo therapies to in vivo candidates, with ongoing phase I studies for CTX310 and CTX320 [2][3] - CTX310 has shown promising results, with reductions of up to 82% in triglycerides and 86% in low-density lipoprotein levels [3][9] Company Developments - Casgevy was developed in partnership with Vertex Pharmaceuticals, which leads global development and commercialization, sharing costs and profits in a 60:40 ratio [2] - CRISPR Therapeutics is expanding its pipeline with plans to advance CTX340 and CTX450 into clinical studies by the end of 2025 [4][9] - The company’s efforts to diversify its pipeline beyond Casgevy are seen as a positive move in the emerging gene therapy market [5] Competitive Landscape - Competition exists from chronic therapies like Bristol Myers' Reblozyl and Novartis' Adakveo for the same indications as Casgevy [5] - Other companies, such as Beam Therapeutics and Intellia Therapeutics, are also developing CRISPR-based therapies, which may pose competitive threats [6][7] Financial Performance - CRSP shares have increased by 34.7% year-to-date, outperforming the industry average rise of 3.2% [8] - The company is currently trading at a price-to-book (P/B) ratio of 2.68, lower than the industry average of 3.10, indicating a potential valuation opportunity [10] - Estimates for CRISPR Therapeutics' loss per share for 2025 have widened from $5.67 to $6.38, while estimates for 2026 have narrowed from $4.42 to $4.02 [11]

Core Insights - CRISPR Therapeutics' Casgevy, a one-shot gene therapy, received approval in late 2023 and early 2024 for sickle cell disease and transfusion-dependent beta-thalassemia in the US and Europe [1] - The partnership with Vertex Pharmaceuticals involves a 60:40 split of program costs and profits, with Vertex leading global development and commercialization [1] Sales Performance - Casgevy had a slow start in 2024, generating only $10 million in full-year product revenues for Vertex, but sales increased significantly to $30.4 million in Q2 2025, marking a 114.1% sequential increase [2][8] - Vertex estimates Casgevy sales to reach approximately $124.6 million in 2025 [2] Treatment Centers and Patient Engagement - Over 75 authorized treatment centers are active for Casgevy, with 115 patients completing their first cell collection as of June 2025 [3][8] Revenue Growth Potential - Increasing Casgevy sales could provide a stable revenue base for CRISPR Therapeutics, allowing for greater investment in its gene-editing pipeline and enhancing long-term growth prospects in the competitive cell and gene therapy market [4][8] Competitive Landscape - Other companies in the gene-editing space include Beam Therapeutics, which is developing BEAM-101 for sickle cell disease, and Intellia Therapeutics, which is advancing in vivo therapies for hereditary angioedema and transthyretin amyloidosis [5][6] Stock Performance and Valuation - CRISPR Therapeutics' shares have increased by 40.7% year-to-date, contrasting with a 0.7% decline in the industry [7] - The company's shares trade at a price-to-book value (P/B) ratio of 2.80, below the industry average of 3.15, but above its five-year mean of 2.38 [9] Earnings Estimates - Loss per share estimates for CRISPR Therapeutics for 2025 have widened from $5.58 to $6.22, while estimates for 2026 have narrowed from $4.30 to $4.03 [10]

Company Overview - Vir Biotechnology, Inc. (VIR) is expected to report a year-over-year increase in earnings driven by higher revenues for the quarter ended June 2025, with a consensus outlook indicating a quarterly loss of $0.72 per share, reflecting a +29.4% change from the previous year [1][3] - Revenues are anticipated to reach $7.64 million, representing a significant increase of 148.1% compared to the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 7.54% higher in the last 30 days, indicating a collective reassessment by analysts [4] - The Most Accurate Estimate for Vir Biotechnology is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -22.91%, suggesting a bearish outlook from analysts [12] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, but the predictive power is significant primarily for positive readings [9][10] - Vir Biotechnology currently holds a Zacks Rank of 3, which complicates the prediction of an earnings beat given the negative Earnings ESP [12] Historical Performance - In the last reported quarter, Vir Biotechnology was expected to post a loss of $0.83 per share but actually reported a loss of -$0.88, resulting in a surprise of -6.02% [13] - Over the past four quarters, the company has only beaten consensus EPS estimates once [14] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Beam Therapeutics Inc. (BEAM) is also expected to report a loss of $1.04 per share for the same quarter, with revenues projected at $13.79 million, up 17.2% year-over-year [18][19] - Beam Therapeutics has an Earnings ESP of -23.08% and a Zacks Rank of 4, indicating challenges in predicting an earnings beat [20]

Industry Overview - Genomics is a rapidly evolving field that studies the complete set of genes and their interactions, attracting significant attention from pharmaceutical and biotech companies [1][2] - The genomics market is projected to reach $157.47 billion by 2033, while the global synthetic biology market was valued at $16.22 billion in 2024 and is expected to grow at a CAGR of 17.30% from 2025 to 2030 [6] Technological Advancements - Breakthroughs in genetic sequencing have drastically reduced the cost, accuracy, and time required to map an individual's genome, leading to innovative applications in healthcare and diagnostics [4] - Genome editing technologies, particularly CRISPR/Cas9, are being developed to treat diseases caused by genetic variants, with companies like CRISPR Therapeutics AG and Beam Therapeutics at the forefront [5] Key Companies - Illumina is a major player in the genomics sector, providing sequencing and array-based solutions for genetic analysis [4] - Intellia Therapeutics focuses on CRISPR-based therapies, with lead candidates targeting ATTR amyloidosis and HAE, and is collaborating with Regeneron for its investigational therapy [8][9][10] - Editas Medicine is developing treatments using its proprietary genome editing platform, with successful preclinical proof of concept for editing hematopoietic stem cells and liver cells [12][13] - Prime Medicine is advancing programs for Wilson's Disease and Alpha-1 Antitrypsin Deficiency, with plans to file for investigational new drugs in 2026 [14][15][16]

Group 1 - ARK Innovation ETF (ARKK) has reached a 52-week high, increasing approximately 92.4% from its 52-week low of $36.85 per share [1] - The ETF focuses on "disruptive innovation," investing in companies involved in DNA technologies, automation, robotics, energy storage, artificial intelligence, and Fintech [1] - Cathie Wood, CEO of Ark Investment Management, has made significant moves by purchasing shares of CRISPR Therapeutics AG and Beam Therapeutics Inc., while selling shares of 908 Devices Inc. and Roku Inc., indicating a bullish stance on gene-editing technologies [2] Group 2 - ARKK shows a weighted alpha of 60.23 and a 20-day volatility of 29.55%, suggesting potential for continued strength and gains for investors [4] - Despite market turbulence, Cathie Wood maintains a positive outlook on the transformative power of emerging technologies [3]

Core Insights - The narrative surrounding the top stock picks has shifted dramatically from March, with a focus now on which stocks can maintain their gains and finish strong in the second half of 2025 [3] Stock Performance Summary - Beam Therapeutics (BEAM) has seen a significant decline of 32.70% year-to-date, with a recent drop of 21.25% in Q1 and 14.70% in Q2 [3] - Bloom Energy (BE) has rebounded with a 9.89% gain in Q2, although it remains below its year-to-date breakeven level [3][5] - Boeing (BA) has shown resilience with a 16.27% increase in Q2, leading to a 12.03% year-to-date gain [3][5] - Carvana (CVNA) has surged with a remarkable 51.87% gain in Q2, resulting in a 56.17% year-to-date increase [3] - CF Industries (CF) has rebounded with a 27.34% gain in Q2, bringing its year-to-date performance to 16.64% [3][6] - Coinbase Global (COIN) has experienced a significant turnaround with a 76.55% gain in Q2, leading to a 22.46% year-to-date increase [3][7] - Dell Technologies (DELL) has gained 30.27% in Q2, with a modest year-to-date increase of 3.04% [3][8] - Deutsche Bank (DB) has performed exceptionally well, with a 62.31% year-to-date gain, including a 16.11% increase in Q2 [3][8] - Nebius Group (NBIS) has surged with a 127.85% gain in Q2, resulting in a 73.83% year-to-date increase [3][9] - Rocket Lab (RKLB) has shown a 66.85% gain in Q2, leading to a 17.17% year-to-date performance [3][10] - Sea Ltd (SE) has maintained a strong performance with a 17.90% gain in Q2, resulting in a 45.00% year-to-date increase [3][11] - STMicroelectronics NV (STM) has seen a nearly 60% increase from its five-year low, supported by a price-target hike [3][12] - Roku Inc (ROKU) has only increased by 10.5% year-to-date, but a new partnership with Amazon could enhance its prospects [3][13] Market Sentiment and Technical Analysis - A total of 13 stocks have transitioned from negative to positive performance in Q2, with only two stocks remaining in the red [3] - The overall total return for the top picks has shifted from a loss of -163% in Q1 to a gain of approximately 271% year-to-date [3] - The market sentiment remains cautious, with lingering negative sentiment from Q1 underperformance affecting some stocks [15] - Stocks like EZPW and Rocket Lab have notable short interest, indicating potential volatility [16]

Core Insights - The recent personnel changes at the FDA's CBER have caused fluctuations in the stock prices of gene editing companies, with a notable decline in Capricor Therapeutics due to its association with the suspended officials [1][2] Group 1: Personnel Changes - The CBER's cell and gene therapy department experienced significant personnel changes, with the director Nicole Weldon and her deputy Rachel Anatol being placed on administrative leave [1] - These changes occurred shortly after the appointment of the new CBER director, Vinay Prasad, who replaced the previously departed Peter Marks [1] - The HHS spokesperson indicated that there were management philosophy disagreements between the suspended officials and Prasad [1] Group 2: Market Reactions - Despite the turmoil at CBER, leading gene editing companies such as Editas Medicine, Intellia Therapeutics, Beam Therapeutics, and CRISPR Therapeutics saw their stock prices rise initially [2] - Conversely, Capricor Therapeutics, which is advancing the cell therapy deramiocel for Duchenne muscular dystrophy, experienced a stock price drop of over 10% due to the involvement of the suspended officials in its drug application process [2]

Core Insights - CRISPR Therapeutics' first marketed product, Casgevy, is a one-shot gene therapy approved for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) in late 2023 and early 2024 [1] - Initial commercial uptake of Casgevy has been modest, with Vertex Pharmaceuticals reporting only $10 million in product revenues for full-year 2024 [2] - The eligible patient population for Casgevy is estimated to be around 60,000, and Vertex is increasing its commercial efforts to support broader access [3] Product Overview - Casgevy is the first approved CRISPR/Cas9 gene-edited therapy, developed in partnership with Vertex Pharmaceuticals, which leads its global development and commercialization [1] - The therapy involves a complex, multi-step process including stem cell collection, ex vivo gene editing, and reinfusion, contributing to its slow adoption [2][7] Competitive Landscape - Casgevy currently faces competition from other gene-editing treatments, such as Beam Therapeutics' BEAM-101 for SCD, which has shown promising results in clinical trials [4] - Additionally, Casgevy competes with established therapies like Bristol Myers' Reblozyl and Novartis' Adakveo, which are available at significantly lower prices compared to Casgevy's $2.2 million [5] Financial Performance - CRISPR Therapeutics' shares have outperformed the industry year to date, indicating positive market sentiment [6] - The company's shares are trading at a price-to-book (P/B) ratio of 2.10, below the industry average of 3.04 and its five-year mean of 2.39, suggesting a valuation discount [8] Earnings Estimates - Estimates for CRISPR's loss per share for 2025 have widened from $5.06 to $5.54, and for 2026, from $3.76 to $4.30 over the past 60 days [10]

Core Insights - Eli Lilly (LLY) announced the acquisition of Verve Therapeutics (VERV), focusing on gene therapies for cardiovascular diseases, particularly VERVE-102, which aims to reduce cholesterol levels [1][9] - The acquisition has positively impacted the share prices of other gene-editing companies, including Crispr Therapeutics (CRSP) and Intellia Therapeutics (NTLA), while Editas Medicine (EDIT) saw a decline [2][9] Gene-Editing Companies Overview - The field of gene editing is rapidly evolving, with companies utilizing CRISPR/Cas9 technology to treat genetic diseases by correcting DNA defects [3] - Intellia Therapeutics (NTLA) focuses on CRISPR-based therapies, with its lead candidates targeting ATTR amyloidosis and hereditary angioedema, and saw a 6.9% increase in share price [4] - Crispr Therapeutics (CRSP) is developing therapies for various diseases and achieved a milestone with the approval of its CRISPR/Cas9 therapy, Casgevy, in November 2023, resulting in a 3.9% share price increase [5] - Beam Therapeutics (BEAM) is advancing base editing programs, including BEAM-101 for sickle cell disease, which received orphan drug designation from the FDA [6] - Editas Medicine is developing treatments using its proprietary CRISPR technology, focusing on in vivo pipeline development [7] Mergers and Acquisitions Activity - Mergers and acquisitions (M&A) in the pharma/biotech sector have increased significantly in 2025, indicating a focus on portfolio expansion and innovation [8][12] - Notable acquisitions include Sanofi's planned acquisition of Blueprint Medicines for up to $9.5 billion and Johnson & Johnson's acquisition of Intra-Cellular Therapies for approximately $14.6 billion [10][11]